(RTTNews) - Telix Pharmaceuticals Limited (TLX.AX) said that the U.S. Food and Drug Administration has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer. The Prescription Drug User Fee Act (PDUFA) goal date is March 24, 2025.
If approved, the new Kit will enable use of a PSMA imaging product with a considerably extended geographic distribution radius from a nuclear pharmacy compared to currently approved gallium-68 based agents, the company said.
PSMA-PET imaging represents a major advancement in prostate cancer management and in the U.S. has replaced conventional imaging methods (bone scan, CT scan) as the standard of care after initial diagnosis and biochemical recurrence.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
